Nanosonics Limited (NNCSF) has received a new Buy rating, initiated by Goldman Sachs analyst, Davinthra Thillainathan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Davinthra Thillainathan’s rating is based on the strong defensive characteristics of Nanosonics Limited’s Trophon franchise, which is contributing to significant margin improvements. These improvements are expected to support the launch of their next major product, CORIS, which aims to address a significant unmet need in infection control. The market currently underestimates the potential of CORIS, despite its advanced cleaning capabilities and the necessity for further investment to enhance its clinical efficacy and automate endoscope reprocessing.
Additionally, the Trophon franchise has introduced new revenue streams and pricing models that have fortified Nanosonics’ competitive position, even with the entry of competitors in the US market. The shift towards recurring revenues is expected to stabilize earnings, and growth in regions like EMEA, Japan, and China is being driven by a third-party distribution model. The recent FDA approval of CORIS underscores its efficacy, although its adoption will require integration into clinical guidelines and partnerships with key manufacturers to enhance market access.
Thillainathan covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Nanosonics Limited, and Healius Limited. According to TipRanks, Thillainathan has an average return of 1.8% and a 53.33% success rate on recommended stocks.
In another report released on September 17, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a A$4.50 price target.